Chester County News and Community Website
YARDLEY, PA — Savara Inc. (Nasdaq: SVRA) will present long-term efficacy and safety findings from its Phase 3 molgramostim trial Sept. 6 at the European Respiratory Society Congress in Barcelona, …
Savara Builds Molgramostim Case With Long-Term Trial Data Read More YARDLEY, PA — Savara Inc. (Nasdaq: SVRA) granted stock options and restricted stock units covering a combined 139,000 shares to eight new employees as the clinical-stage biotechnology company continues development …
Savara Grants Equity Awards to Eight New Employees Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) reported a wider second-quarter loss as the rare-disease drug developer expanded its commercial operation ahead of a November 22 U.S. regulatory decision on …
Savara Loss Widens as Lung Drug Nears FDA Decision Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) secured patent protection in Europe and Australia through March 2041 for the liquid formulation of its investigational lung-disease therapy MOLBREEVI, expanding the intellectual-property …
Savara Extends MOLBREEVI Patent Protection to 2041 Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) granted equity awards covering 87,000 shares of company stock to four newly hired employees, using inducement incentives as the clinical-stage biotechnology company advances …
Savara Grants Equity Awards to New Hires Amid Growth Push Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) is restructuring its executive leadership team after Chief Financial and Administrative Officer Dave Lowrance stepped down for health-related reasons, placing Chief Operating Officer …
Savara Shifts Finance Leadership Ahead of Key Drug Milestone Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) reported new Phase 3 clinical trial data showing its experimental therapy molgramostim improved lung function and reduced disease-associated biomarkers in patients with autoimmune …
Savara Reports Phase 3 Biomarker Gains for Rare Lung Disease Read More LANGHORNE, PA — Savara (Nasdaq: SVRA) reported long-term Phase 3 trial data showing continued improvements in lung function and respiratory quality of life among patients receiving molgramostim for autoimmune pulmonary …
Savara Reports Long-Term Phase 3 Data Supporting Molgramostim Durability Read More LANGHORNE, PA — Savara (Nasdaq: SVRA) reported new Phase 3 clinical trial data showing patients treated with its experimental inhaled therapy molgramostim achieved greater improvements in exercise capacity than those …
Savara Reports Phase 3 Data Showing Exercise Gains in Rare Lung Disease Trial Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) advanced regulatory filings for its lead rare lung disease therapy MOLBREEVI while reporting a wider first-quarter loss as the company ramps up manufacturing …
Savara Advances MOLBREEVI Toward FDA Decision as Loss Widens Read More